

Summary of minutes of EUCAST Steering Committee Meeting Växjö, Sweden, 8-9 September 2008

Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Cantón	RC	Clinical Data Co-ordinator	Spain
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Dr Christian Giske	CG	SRGA	Sweden
Dr Antti Hakanen	AH	EUCAST	Finland
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Arne Rodloff	AR	DIN	Germany
Prof Claude-James Soussy	CS	CA-SFM	France
Dr Martin Steinbakk	MS	NWGA	Norway
Prof Paul Tulkens	PT	EUCAST	ISC

1	<p>Chairman's welcome GK welcomed Dr Christian Giske as new representative of the SRGA.</p>
2	<p>Minutes of meeting of 12-13 June 2008 The minutes were accepted as a correct record.</p>
3	<p>Matters arising from minutes of 12-13 June 2008 Minocycline MIC data for <i>H. influenzae</i> is being collected.</p> <p>The next version of the WHOnet program may be able to export data in the EUCAST Excel format.</p> <p>Quinupristin-dalfopristin MIC distributions are being sought.</p> <p>There are no current plans to extend the license for moxifloxacin to anaerobic intra-abdominal infections.</p> <p>Anaerobe MIC distributions have been added to the wild type MIC distributions website.</p> <p>Dosing of a new cephalosporin is being questioned.</p> <p>For anaerobes, breakpoints were added for some beta-lactam agents and IE for phenoxymethyl penicillin</p> <p>A response from the company to proposed EUCAS breakpoints for a new glycopeptide is still awaited.</p> <p>A reply has been received from the company regarding why MICs for a new cephalosporin for <i>P. vulgaris</i> are significantly higher by broth dilution than by agar dilution.</p> <p>The revised carbapenem table with doripenem breakpoints will be released soon.</p> <p>The voriconazole rationale document was sent for consultation.</p> <p>Penicillin breakpoints: Replies are being received to a questionnaire to the General Committee asking for the doses of penicillins commonly used for CAP caused by <i>S. pneumoniae</i>. A table will be produced with different doses and Pk/Pd breakpoints covering the dosage range. In the absence of outcome data for viridans streptococci isolates with benzylpenicillin MICs 4-8 mg/L it was agreed not to change proposed breakpoints at present. Data supporting amoxicillin breakpoints of 0.25/2 mg/L for meningococci to avoid reporting amoxicillin resistant, ampicillin susceptible are being examined. The penicillin table was revised before release on the website.</p> <p>A separate breakpoint column has been added for streptococci other than Groups A, B, C, G and <i>S. pneumoniae</i>. Some gaps in breakpoints will need to be filled.</p>

Some MIC distributions for *Clostridium difficile* have been received but more would be welcome.

No MIC distributions for *H. pylori* have yet been received from expert groups.

Data regarding colistin breakpoints for *Pseudomonas* spp. are being sought.

4 New drugs

Company responses to proposed EUCAST breakpoints for a new quinolone were discussed.

There has been no response from the company to proposed EUCAST breakpoints for a new glycopeptide.

The application for licensing of dalbavancin has been withdrawn by Pfizer.

A formal presentation to EUCAST of a new glycopeptide has been scheduled for November 2008.

A formal presentation to EUCAST of a new diaminopyrimidine agent has been scheduled for November 2008.

The licensing process for a new cephalosporin is in progress.

5 Status of EUCAST documents The current status of documents was reviewed.

6 Expert rules subcommittee The intention is to publish the supplement in CMI early in 2009. It was agreed that the rules should be updated in time for publication in the supplement. A computer program for application of the rules is being developed. Methods of detection of specific resistance mechanisms will not be included with expert rules.

7 Antifungal susceptibility testing subcommittee Discussions are underway regarding posaconazole and itraconazole breakpoints.

8 Anaerobe subcommittee No new information.

9 Mycobacterium subcommittee Funding is available for this subcommittee. The exact remit and structure are to be defined.

10 Request from Aventis for telithromycin rationale document The rationale for telithromycin harmonised breakpoints has been requested.

11 Organisms/agents requiring breakpoints There have been few replies from the General Committee regarding whether any EUCAST breakpoints need review and whether there are any other organism-antibiotic combinations that should have breakpoints. The invitation will remain open until the end of the year.

12 CLSI Noted that CLSI may be coming to an arrangement with the FDA over breakpoint setting.

13 ESCMID A EUCAST Postgraduate Educational Workshop is unlikely before 2010. A EUCAST workshop at ECCMID 2009 has been agreed and participants invited. A EUCAST symposium at ECCMID 2009 on implementation of EUCAST breakpoints will be offered to the organisers.

14 EUCAST disk diffusion method A "call for tenders" is expected from ECDC before the end of the year. ESCMID is supporting preliminary work.

15 ECDC has accepted the EUCAST-ESCMID proposal for a European Susceptibility Organisation. Funding will be for 3 years and it is expected that a representative of ECDC will attend Steering Committee meetings.

16 EMEA will give a presentation to the Steering Committee in November on the EMEA regulatory process.

- | | |
|-----------|---|
| 17 | EUCAST MIC tables MIC breakpoint tables would be provided on the EUCAST website in pdf format so that formatting is maintained. It will be possible to print all tables together. |
| 18 | Oral cephalosporins Draft breakpoints were reviewed. The draft breakpoints will be discussed again at the next meeting in November and will then be sent out for general consultation. |
| 19 | Revision of carbapenem breakpoints Evidence for changing breakpoints is not conclusive and breakpoints will not be changed at this time. Draft rationale documents are being updated. |
| 20 | Revision of glycopeptide breakpoints Proposed revised breakpoints will be sent for consultation with a note on why the changes have been made. |
| 21 | Any other business Guidance on when additional testing, such as MICs, is appropriate will be produced for the disk diffusion method. |
| 22 | Next meetings
24-25 November 2008.
6-17 February 2009. Madrid, Spain
19-20 May 2009. Helsinki, Finland (following ECCMID)
7-8 September 2009. Leipzig/Munich, Germany
23-24 November 2009. Nice, France |

Ratified summary of minutes of meeting 8-9 September 2008. Prepared by DB, GK and RC

Dr Derek F.J. Brown Health Protection Agency Clinical Microbiology and Public Health Laboratory Addenbrooke's Hospital, Hills Road Cambridge CB2 0QW United Kingdom	Scientific Secretary Tel: +44 1223 257020 Mobile: +44 7762 746692 Fax: +44 1223 242775 Email: dfjb2@cam.ac.uk
Dr. Rafael Cantón Servicio de Microbiología Hospital Universitario Ramón y Cajal Carretera de Colmenar Km 9,1 28034-Madrid Spain	Clinical Data Co-ordinator. Tel: + 34 913 368 330 Mobile: + 34 619 235 954 Fax: + 34 913 368 809 Email: rcanton.hrc@salud.madrid.org
Professor Luc Dubreuil Clinical Bacteriology Department, Faculté de Pharmacie, BP83, 59006 Lille CEDEX, France	Tel: +33 Mobile: +33 Fax: +33 Email: luc.dubreuil@univ-lille2.fr
Dr Antti Hakanen National Public Health Institute Kiinamyllynkatu 13 FIN-20520 Turku Finland	Tel: + 358 2 331 6600 Mobile: +358 40 531 6953 Fax: +358 2 331 6699 Email: antti.hakanen@utu.fi
Professor Gunnar Kahlmeter Klinisk mikrobiologi Centrallasarettet 351 85 Växjö Sweden	Chairperson Tel: +46 470587477 Mobile: +46 709844685 Fax: +46 470587455 Email: gunnar.kahlmeter@ltkronoberg.se
Professor Alasdair P. MacGowan Department of Medical Microbiology Southmead Hospital Westbury on Trym Bristol BS10 5NB United Kingdom	Tel: +44 117 959 5651 Mobile: +44 7919 337856 Fax: +44 117 959 3154 Email: alsadair.macgowan@north-bristol.swest.nhs.uk Email: joanne.cook@north-bristol.swest.nhs.uk (secretary)
Dr Johan W. Mouton, Dept Medical Microbiology and Infectious Diseases Canisius Wilhelmina Hospital C-70 Weg door Jonkerbos 100 6532 sz Nijmegen The Netherlands	Tel: +31 24 3657514 Mobile: +31 651381270 Fax: +31 24 3657516 Email: mouton@cwz.nl
Dr Christian Giske, Department of clinical microbiology L2:02 Karolinska University Hospital, Solna SE-17176 Stockholm Sweden	Tel: +46 8 517 73574 Mobile: +46 Fax: +46 8 30 80 99 Email: christian.giske@karolinska.se
Prof Claude-James Soussy Hôpital Henri Mondor Service de Bactériologie 51 Av De Lattre De Tassigny Creteil 94010 France	Tel: +33 149812831 Mobile: Fax: Email: claudesoussy@hmn.ap-hop-paris.fr
Professor Arne C. Rodloff Inst für Medizinische Mikrobiologie der Universität Leipzig Liebigstr 24 Leipzig 04103 Germany	Tel: +49 3419715200 Mobile: +49 175 365 6650 Fax: +49 3419715209 Email: acr@medizin.uni-leipzig.de
Dr Martin Steinbakk Department of Microbiology Akershus University Hospital P.O. Box 23 N-1478 Lørenskog Norway	Tel: +47 67 928 500 Mobile: +47 913 97667 Fax: +47 67 928 519 Email: martin.steinbakk@ahus.no Email: drmartin@online.no
Professor Paul M. Tulkens Unité de Pharmacologie Université Catholique de Louvain UCL 7370 avenue E. MOUNIER B-1200 Bruxelles Belgium	Tel: +32 2 762 21 36 or 764 73 71 Mobile: Fax: +32 2 764 73 73 Email: tulkens@facm.ucl.ac.be